Aliskiren & amlodopine combination treatment for hypertension v1.0

• Research type

  Research Study

• Full title

  A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the sequential add-on treatment strategies in patients with essential hypertension. (CSPA100A2307, ACCELERATE)

• IRAS ID

  7911

• Contact name

  Nicola Lister

• Contact email

  nicola.lister@novartis.com

• Sponsor organisation

  Novartis Pharmaceutical Services AG

• Eudract number

  2008-004242-83

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  08/H0502/131

• Date of REC Opinion

  28 Oct 2008

• REC opinion

  Further Information Favourable Opinion